Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Research & Development (2019 - 2025)

Addex Therapeutics' Research & Development history spans 7 years, with the latest figure at $1.6 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 13.92% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $872419.2, a 11.31% decrease, with the full-year FY2025 number at $810097.4, down 16.93% from a year prior.
  • Research & Development came in at $1.6 million for Q4 2025, up from -$285427.5 in the prior quarter.
  • The five-year high for Research & Development was $24.1 million in Q4 2021, with the low at -$6.0 million in Q2 2022.
  • Historically, Research & Development has averaged $1.3 million across 5 years, with a median of -$284311.1 in 2025.
  • Peak annual rise in Research & Development hit 94.57% in 2023, while the deepest fall reached 88.23% in 2023.
  • Year by year, Research & Development stood at $24.1 million in 2021, then dropped by 11.46% to $21.3 million in 2022, then tumbled by 88.23% to $2.5 million in 2023, then dropped by 25.19% to $1.9 million in 2024, then decreased by 13.92% to $1.6 million in 2025.
  • Business Quant data shows Research & Development for ADXN at $1.6 million in Q4 2025, -$285427.5 in Q3 2025, and -$283194.7 in Q2 2025.